enGene Holdings Inc. (ENGN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Saint-Laurent, Canada. The current CEO is Ronald H. W. Cooper.
ENGN has IPO date of 2022-02-01, 56 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $397.27M.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
